Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Beyondspring, inc. save search
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Published: 2022-12-13 (Crawled : 20:00) - biospace.com/
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 17.2%
H: 35.14%
C: 15.99%
lung plinabulin breast medical positive cancer
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherapy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 14:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive therapy cancer conference plinabulin
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 12:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive cancer conference plinabulin
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: -19.1%
H: 7.65%
C: -16.07%
positive phase 3 plinabulin
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
Published: 2021-09-20 (Crawled : 12:00) - globenewswire.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: -19.1%
H: 7.65%
C: -16.07%
lung cancer europe positive cancer phase 3 plinabulin
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Published: 2021-09-16 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.35%
H: 0.95%
C: -2.34%
europe positive therapy plinabulin
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-10 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: -0.09%
H: 3.35%
C: 0.26%
positive phase 3 plinabulin
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.75%
H: 4.39%
C: 1.31%
breast cancer cancer positive results phase 3 trial trial results symposium
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.